Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

The community needs you

Question: Who is responsible for sharewise?

sharewise was initially founded by me, Stefan Nothegger, in 2007. A few years later sharewise was sold to the Japanese company Minkabu. In 2019 Minkabu decided to focus solely on the Japanese market and therefore to shut down the platform. Due to the committed user base which is very fond of sharewise I have decided to continue the platform together with my brother Christoph. This necessitated a complete rebuild of the platform from the ground up, which I have done in my spare time.

Additional FAQs

Portfolios of our members

Phoenics Invest
Total
€132,277
Cash
€13,570
Performance (%)
32.277%
Name Username Total Performance (%) Typ
Phoenics Invest phoenics  €132,277 32.277% Mid Cap
Langfristiges Depot (Asien) bis 2032 thorstenm  €317,200 217.200% Small Cap
Treat Yo Self (10K Starting / 90K Cash Minimum) MyKeyTheGreat  €98,583 -1.417% Small Cap
Test stachr  €99,991 -0.009% Large Cap
Depot1 gianroswi  €97,457 -2.543% Large Cap

Predictions

buy
Copa Holdings S.A.

Start price
Target price
Perf. (%)
€116.50
11.08.26
€160.23
11.08.27
-
11.08.26

buy
Zoetis Inc. A

Start price
Target price
Perf. (%)
€65.10
11.08.26
€83.15
11.08.27
0.00%
07:30

buy
Matador Resources

Start price
Target price
Perf. (%)
€45.58
11.08.26
€51.97
11.08.27
0.00%
11.08.26

buy
Ipg Photonics

Start price
Target price
Perf. (%)
€74.28
11.08.26
€118.66
11.08.27
0.00%
11.08.26

Contest

Compete in Catch the Monkey ...

... and win a prize!

Users with extraordinary achievements

Pros and Cons of these stocks (New Predictions)

Beyond Meat Inc

WKN: A2N7XQ / Symbol: BYND / Name: Beyond Meat / Stock / Mid Cap /

Pros
4
Some uniques
6
Future proof or reliable business model
2
Differentiated customer and product portfolio
Cons
2
negative Cash Flow expected
3
Lower EBIT Margin than peer group
1
Very low/no dividend yield expected
Silence Therapeutics plc ADR

WKN: A2QB4J / Symbol: SLN / Name: Silence Therapeutics / Stock / Mid Cap /

Pros
2
Could be worthwhile Investment >10% per year
Cons
Try sharewise+ and get hundreds more matching stocks
Sign up for free!